хендай солярис цена в краснодаре в автосалонах цены
Главное меню:
Интересное
хендай солярис цена в краснодаре в автосалонах цены, Excellent outcomes in children and adolescents with CNS, Burkitt’s Lymphoma | New England Journal of Medicine, Excellent outcomes in children and adolescents with central nervous , Rituximab with chemotherapy in children and adolescents with central , Excellent outcomes in children and adolescents with CNS+ Burkitt , Excellent outcomes in children and adolescents with CNS+ Burkitt , Excellent outcomes in children and adolescents with CNS+ burkitt .
Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC, Harrison L, Pinkerton R, Raphael M, McCarthy K, Perkins SL & Patte C (2012) Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>/= 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. Journal of Clinical Oncology, 30, 387–393., Excellent outcomes in children and adolescents with CNS + Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1 Br J Haematol. 2019 Apr;185 (2):374-377. doi: 10.1111/bjh.15520. Epub 2018 Aug 16., More than 90% of children and adolescents are cured with highly dose-intensive chemotherapy, whereas adults are more susceptible to the toxic effects of treatment, and prospective trials have.
In this recent study, patients with CNS disease with or without CSF blasts did equally well. , Based on the results of this trial, an international randomized study of FAB/LMB 96 chemotherapy ± rituximab for high-risk patients is currently under investigation., Here, we present high‐risk CNS + patient data from both the FAB/LMB96 C 1 ‐arm and COG‐ANHL01P1 and compare them to prior LMB89 results. Overall, excellent EFS and OS were achieved, with further improvement with rituximab., Excellent outcomes in children and adolescents with CNS+ Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1, Author: Frazer, J. Kimble Author: Li, Kevin J. Author: Galardy, Paul J. Author: Perkins, Sherrie L., In this review we will summarize the results from recent therapeutic clinical trials, describe the evidence to support the inclusion of rituximab and review the rationale for the investigation of several new categories of novel agents for mature B cell lymphomas in children and adolescents..